Please try another search
Rapid Dose Therapeutics Corp. reported earnings results for the second quarter and six months ended August 31, 2023. For the second quarter, the company reported sales was CAD 0.353171 million compared to CAD 0.133554 million a year ago. Net loss was CAD 0.730685 million compared to CAD 0.91452 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.For the six months, sales was CAD 0.593958 million compared to CAD 0.19532 million a year ago. Net loss was CAD 1.3 million compared to CAD 1.92 million a year ago. Basic loss per share from continuing operations was CAD 0.01.
Period Ending: | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 |
---|---|---|---|---|
Total Revenue | 0.217 | 0.306 | ||
Gross Profit | 0.029 | 0.227 | ||
Operating Income | -1.16 | -0.532 | ||
Net Income | -0.567 | -1.3 | -0.584 |
Period Ending: | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 |
---|---|---|---|---|
Total Assets | 2.25 | 2.74 | ||
Total Liabilities | 5.94 | 4.92 | 4.16 | |
Total Equity | -2.67 | -1.43 |
Period Ending: | Aug 31, 2023 | May 31, 2023 | Feb 28, 2023 | Nov 30, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -0.09 | -0.119 | ||
Cash From Investing Activities | ||||
Cash From Financing Activities | 0.138 | 0.091 | 0.129 | |
Net Change in Cash | 0.005 | 0.001 | 0.01 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review